background
synthet
probe
mimic
natur
substrat
enabl
detect
enzymat
activ
cellular
environ
one
area
activitybas
probe
appli
ubiquitinproteasom
pathway
emerg
import
therapeut
target
famili
reagent
develop
specif
label
deubiquityl
enzym
dub
facilit
character
inhibitor
scope
review
focu
applic
probe
intracellular
dub
group
specif
proteas
involv
ubiquitin
proteasom
system
particular
function
character
activ
subunit
famili
proteas
specif
recogn
ubiquitin
ubiquitinlik
protein
discuss
addit
present
potenti
design
activitybas
probe
target
kinas
phosphatas
studi
phosphoryl
major
conclus
synthet
molecular
probe
increas
understand
function
role
dub
live
cell
addit
detect
enzymat
activ
known
member
activitybas
probe
contribut
number
function
assign
previous
uncharacter
enzym
method
enabl
cellular
valid
specif
small
molecul
dub
inhibitor
gener
signific
molecular
probe
combin
mass
spectrometrybas
proteom
cellular
assay
repres
power
approach
discoveri
function
valid
concept
expand
enzym
class
address
need
inform
cellbas
assay
requir
acceler
drug
develop
process
articl
part
special
issu
entitl
ubiquitin
drug
discoveri
diagnost
like
protein
ubiquitin
carboxyl
termin
hydrolas
isozym
ubiquitin
carboxyl
termin
hydrolas
isozym
ubiquitin
carboxyl
termin
hydrolas
isozym
ubiquitin
specif
process
proteas
last
two
decad
wit
develop
applic
activ
base
probe
detect
enzymat
activ
relat
wide
rang
protein
posttransl
modif
ptm
tool
allow
detect
mani
enzymat
activ
relat
conjug
deconjug
ptm
greatest
success
widest
applic
approach
probabl
found
within
ubiquitin
proteasom
pathway
ubiquitin
proteasom
system
up
consist
three
differ
element
partial
oppos
complementari
role
ubiquitin
conjug
cascad
deubiquityl
enzym
proteasom
complex
fig
ubiquitin
conjug
cascad
enzym
respons
conjug
ubiquitin
ub
ubiquitinlik
protein
ubl
protein
signal
molecul
sever
biolog
process
deubiquityl
enzym
dub
respons
remov
trim
edit
ububl
modif
protein
proteasom
complex
compos
least
three
differ
proteolyt
activ
subunit
degrad
major
solubl
protein
within
cell
follow
polyubiquityl
up
enabl
target
destruct
protein
longer
requir
cell
also
enabl
select
deactiv
signal
molecul
remov
pathogen
protein
product
peptid
present
immun
system
entir
pathway
compris
close
gene
vital
mani
normal
cellular
function
frequent
disrupt
cellular
patholog
like
explan
remark
success
develop
activitybas
probe
up
compar
small
molecul
probe
relat
ptm
abil
target
cystein
threonin
proteas
success
coval
inhibit
repres
major
enzymat
activ
dub
proteasom
respect
improv
recognit
proteinbas
ubiquitin
peptidederiv
proteasom
probe
compar
small
molecul
base
probe
may
also
contribut
gener
activ
base
probe
ubiquitin
pathway
import
tool
obtain
insight
ubiquitin
proteasom
system
review
previous
focu
review
applic
activitybas
probe
context
inhibitor
develop
character
process
repres
critic
step
arriv
better
understand
fundament
cellular
process
enabl
develop
novel
target
therapeut
agent
activitybas
probe
abp
defin
abil
target
subset
complex
proteom
base
label
specif
enzym
class
coval
fashion
incorpor
specif
tag
detect
enrich
allow
visual
analysi
exampl
tandem
mass
spectrometri
abp
approach
highli
complementari
mass
spectrometrybas
proteom
due
abil
enrich
specif
captur
substrat
aid
affin
tag
also
distinguish
method
use
radiolabel
coval
inhibitor
support
detect
affin
enrich
critic
paramet
also
choic
reactiv
group
coval
label
target
enzym
close
enzym
activ
site
depend
mechan
enzymat
catalysi
differ
reactiv
group
chosen
coval
captur
alkyl
nucleophil
residu
cy
ser
thr
present
proteas
activ
site
reactiv
electrophil
success
realiz
method
util
abp
particularli
evid
studi
enzym
system
involv
attach
remov
ptm
due
enzym
activ
site
chemistri
involv
abp
develop
gener
fruit
target
deconjug
enzym
usual
contain
strong
nucleophil
activ
site
compar
respect
ligasestransferas
discoveri
develop
proteasom
inhibitor
previous
cover
comprehens
review
therefor
give
brief
introduct
proteasom
complex
proteasom
activ
site
probe
proteolyt
activ
site
proteasom
complex
locat
distinct
subunit
exampl
constitut
proteasom
reflect
label
pattern
obtain
activ
sitedirect
proteasom
probe
three
subunit
respons
proteolysi
also
correspond
differ
activ
profil
respect
substrat
specif
name
prototyp
proteas
chymotrypsinlik
activ
ctl
trypsinlik
activ
tl
petidylglutamyl
peptid
hydrolyzinglik
pgphl
activ
also
refer
caspaselik
exchang
activ
subunit
close
homologu
induc
immun
cell
thymu
allow
tune
peptid
repertoir
produc
proteasom
proteolysi
underscor
import
present
peptid
process
step
immun
surveil
proteolyt
activ
subunit
proteasom
target
probe
base
peptid
scaffold
bear
ctermin
electrophil
fig
popular
design
base
trileucin
vinylsulfon
l
vs
substructur
function
epoxomicin
deriv
profil
probe
enabl
detect
dansyl
biotin
tag
strong
fluorophor
well
radiolabel
altern
two
step
protocol
appli
wherebi
tag
attach
bioorthogon
ligat
step
follow
label
activ
proteasom
subunit
cell
lysat
select
ligat
possibl
applic
stauding
ligat
format
also
known
click
chemistri
recent
addit
arsen
proteasomedirect
probe
belacostin
deriv
probe
contain
probe
use
success
label
subunit
proteasom
hela
cell
well
proteasom
erythrocyt
ubiquitin
deriv
abp
use
profil
activ
dub
popul
cell
line
primari
cell
tissu
subsequ
concept
extend
studi
proteas
specif
ubiquitinlik
protein
ubl
complex
proteom
cell
tissu
lysat
label
incub
ubiquitin
probe
follow
sdspage
separ
immunoblot
epitop
tag
genet
encod
probe
construct
therebi
readout
depend
dub
abund
activ
obtain
approach
also
extend
investig
cancer
cell
line
patient
biopsi
particularli
fruit
studi
vitro
infect
model
viral
parasit
bacteri
pathogen
way
previous
unknown
dub
encod
pathogen
identifi
interact
pathogen
encod
factor
host
ubiquitin
proteasom
system
elucid
dub
relat
pathogenhost
interact
review
detail
elsewher
ubiquitin
probe
enabl
structur
studi
dububiquitin
complex
investig
crystal
xray
diffract
coval
adduct
form
enzym
ubiquitin
probe
allow
insight
molecular
determin
interact
dub
ubiquityl
substrat
type
studi
also
success
carri
complex
involv
ubiquitin
aldehyd
ubiquitin
probe
devoid
epitop
tag
addit
util
ubiquitin
abp
target
cy
proteas
dub
msbase
proteom
experi
ubiquitin
probe
also
shown
retriev
regul
ubiquityl
exampl
metalloproteas
dub
retriev
nativ
pulldown
condit
find
might
explain
format
noncoval
complex
enrich
immunoprecipit
ip
nondenatur
condit
target
retriev
ubiquitin
ligas
ubiquitin
probe
also
observ
usual
reduc
nucleophil
cy
residu
enzym
class
compar
cy
part
catalyt
triad
dub
proteas
result
strongli
reduc
captur
appar
compens
certain
extend
strong
ctermin
electrophil
conjug
ub
probe
addit
abovement
applic
activitybas
proteom
probe
also
enabl
develop
pharmacolog
activ
enzym
inhibitor
one
format
competit
assay
inhibitor
candid
compound
activitybas
probe
perform
cell
lysat
type
assay
format
competit
small
molecul
inhibitor
probe
lead
reduc
label
profil
activitybas
probe
loss
signal
label
specif
target
enzym
allow
assess
specif
inhibit
titrat
concentr
rang
provid
measur
ic
valu
respect
inhibitor
sever
featur
make
type
assay
format
particularli
attract
approach
repres
cellbas
assay
treatment
inhibitor
candid
perform
intact
cell
contrast
major
vitro
enzym
assay
rang
activ
cellular
enzym
assay
simultan
limit
number
enzym
success
label
activitybas
probe
represent
activ
enzym
cellular
proteom
quantifi
result
obtain
use
variou
readout
format
includ
immunoblot
ingel
fluoresc
detect
ip
follow
quantit
msbase
proteom
approach
employ
success
number
abp
includ
identif
character
select
inhibitor
proteasom
cystein
proteas
dub
enzym
famili
serin
hydrolas
fatti
acid
amid
hydrolas
class
promiscu
inhibitor
test
way
order
demonstr
broad
inhibit
profil
competit
assay
appli
character
specif
known
drug
develop
novel
cancer
therapeut
prime
exampl
success
bortezomib
treatment
multipl
myeloma
provid
proof
concept
valu
intervent
target
ubiquitin
proteasom
system
effect
bortezomib
activ
composit
proteasom
multipl
myeloma
cell
investig
label
proteasom
probe
ada
yahx
l
vs
demonstr
inhibitor
select
target
subunit
well
immunoproteasom
subunit
correspond
experi
carri
presenc
absenc
cytokin
induc
format
immunoproteasom
condit
may
encount
bone
marrow
similar
character
subunit
specif
proteasom
inhibit
also
carri
oral
activ
inhibitor
salinosporamid
multipl
myeloma
cell
result
competit
label
proteasom
probe
dansylahx
l
vs
indic
inhibitor
target
subunit
result
consist
find
cleavag
fluorogen
substrat
show
inhibit
ctl
tl
pgphl
activ
proteasom
compar
studi
specif
three
proteasom
inhibitor
bzlllcocho
bortezomib
assess
label
cell
permeabl
dansylahx
l
vs
probe
follow
treatment
individu
inhibitor
h
demonstr
clearli
distinct
label
pattern
proteolyt
activ
proteasom
subunit
three
inhibitor
observ
label
pattern
posit
correl
inhibit
ctl
tl
pgphl
activ
proteasom
hydrolysi
suitabl
fluorogen
substrat
presenc
inhibitor
select
inhibit
immunoproteasom
subunit
synthet
dihydroeponemycin
analog
demonstr
competit
label
experi
cell
use
biotinepoxomicin
biotineponemycin
proteasom
activ
site
probe
exampl
highlight
valu
util
activ
sitedirect
probe
develop
character
proteasom
inhibitor
enabl
abil
provid
rapid
assay
correspond
proteolyt
activ
subunit
differ
cell
type
presenc
absenc
ad
competit
inhibitor
specif
therebi
assess
approach
inform
basic
scienc
well
develop
lead
compound
novel
therapeut
due
larg
number
cellular
dub
need
innov
assay
design
allow
assess
dub
activ
cellular
context
competit
label
ub
probe
provid
character
lead
compound
cell
cultur
model
therebi
provid
valuabl
data
assess
compound
potenc
select
differ
dub
relev
given
cell
type
number
dub
inhibitor
character
develop
lead
compound
medicin
chemistri
program
gener
initi
hit
obtain
high
throughput
screen
ht
compound
librari
follow
optim
use
structureact
relationship
noteworthi
mani
identifi
lead
compound
inhibitor
abil
coval
label
activ
site
cystein
residu
present
major
dub
fig
may
occur
conjug
addit
nucleophil
aromat
substitut
disulfid
bond
format
depend
chemistri
small
molecul
inhibitor
one
exampl
ub
probe
label
presenc
small
molecul
inhibitor
character
partial
select
dub
inhibitor
induc
aggresom
format
tumor
cell
apoptosi
kapuria
et
al
select
inhibit
differ
member
dub
famili
enzym
also
investig
vitro
inhibit
assay
use
ubamc
substrat
combin
recombin
purifi
dub
total
cellular
dub
activ
lysat
treat
inhibitor
test
ubamc
hydrolysi
label
treat
versu
untreat
cell
lysat
activitybas
probe
haubv
perform
order
assess
dub
inhibitori
profil
assay
format
reduc
label
haubv
probe
detect
antiha
immunoblot
lysat
cell
treat
use
readout
select
dub
inhibit
focu
work
observ
accumul
polyubiquityl
protein
materi
upon
treatment
despit
lack
inhibit
proteasom
activ
altun
et
al
describ
extens
applic
activitybas
probe
character
develop
novel
dub
inhibitor
studi
two
dub
inhibitor
character
vitro
enzym
inhibit
assay
cell
cultur
model
label
cell
lysat
treat
inhibitor
vari
concentr
perform
ubiquitin
probe
haubvm
investig
dub
inhibit
profil
readout
assay
immunoblot
hatag
specif
dub
interest
carri
enabl
rapid
assess
inhibitor
specif
order
obtain
altern
quantit
readout
format
antiha
immunoprecipit
ip
combin
identif
labelfre
quantif
mass
spectrometri
base
proteom
fig
use
approach
quantit
data
illustr
degre
inhibit
cellular
dub
obtain
data
consist
vitro
enzym
character
data
demonstr
exhibit
broad
inhibit
profil
wherea
select
inhibitor
consid
oncolog
target
relat
analog
subject
develop
anticanc
therapeut
anoth
applic
ub
probe
label
develop
inhibitor
recent
demonstr
reverdi
et
al
screen
hit
hbx
identifi
high
throughput
screen
ht
compound
librari
employ
ubamc
assay
character
haubv
label
cell
treat
increas
concentr
inhibitor
readout
assay
perform
antiha
immunoblot
show
reduc
probe
label
leav
competit
label
cellular
dub
unaffect
result
consist
vitro
enzym
inhibit
data
also
indic
lack
inhibit
test
cystein
proteas
dub
ubl
specif
proteas
activ
hbx
toward
close
relat
dub
discuss
mechan
inhibit
investig
author
coval
label
activ
site
demonstr
indic
alkyl
residu
lead
irrevers
inactiv
dub
furthermor
cellular
effect
inhibitor
character
reduct
cell
prolifer
induct
apoptosi
arrest
dosedepend
fashion
novel
dub
inhibitor
recent
describ
darci
et
al
dub
profil
carri
presenc
ubiquitin
probe
haubv
cell
h
treatment
inhibitor
demonstr
lesser
extend
inhibit
concentr
treatment
cell
led
tumor
cell
apoptosi
independ
statu
addit
accumul
high
molecular
weight
ub
conjug
reduc
level
free
ubiquitin
observ
ascrib
inhibit
associ
dub
author
conclud
compound
act
broad
spectrum
dub
inhibitor
concentr
employ
rather
inhibit
proteasom
associ
dub
thu
effect
inhibit
proteasom
activ
inhibit
dub
process
polyubiquityl
protein
prior
engag
proteasom
approach
util
viral
dub
well
ubiquitin
probe
haubv
success
appli
demonstr
select
inhibitor
sar
coronaviru
proteas
isopeptidas
papainlik
proteas
plpro
vero
cell
lysat
chang
label
profil
observ
cellular
dub
inhibitor
concentr
contrast
label
ad
plpro
almost
complet
abolish
inhibitor
concentr
use
activ
base
probe
abp
develop
character
enzym
inhibitor
also
recogn
field
outsid
ubiquitin
proteasom
system
describ
advanc
made
applic
concept
kinas
phosphatas
involv
protein
phosphoryl
abp
target
kinas
phosphatas
receiv
consider
attent
due
central
role
protein
phosphoryl
cellular
signal
protein
transloc
ultim
aberr
diseas
initi
kinas
probe
util
atp
adp
analog
molecular
scaffold
therebi
target
essenti
kinas
cofactor
probe
design
later
approach
built
modif
known
kinas
inhibitor
natur
product
origin
relat
licens
drug
kinas
probe
base
acyl
phosphat
atp
adp
analog
lead
transfer
biotin
amino
acid
residu
interact
protein
result
label
identif
rang
kinas
atpas
nucleotid
biosynthesisrel
protein
lack
select
kinas
cellular
environ
understand
given
wide
rang
protein
util
atp
cofactor
tetramethylrhodaminelabel
wortmannin
analog
allow
label
mammalian
cell
lysat
readout
assay
gel
fluoresc
fluoresc
kinas
probe
label
dna
depend
protein
kinas
dnapk
phosphoinositid
kinas
mammalian
pololik
kinas
previous
appreci
inhibit
wortmannin
relev
concentr
wortmannin
deriv
label
borondipyrromethen
bodipi
tetramethylrhodamin
biotin
prepar
success
shown
bodipi
deriv
cellperm
therebi
enabl
label
intact
cell
biotin
deriv
allow
isol
label
protein
materi
cell
lysat
followup
studi
work
liu
et
al
also
demonstr
pololik
kinas
molecular
target
wortmannin
shown
competit
label
wortmannin
label
site
determin
tandem
mass
spectrometri
found
repres
conserv
lysin
residu
atp
bind
site
kinas
bisindolylmaleimid
motif
chosen
scaffold
design
kinas
probe
recognit
motif
high
affin
protein
kinas
c
pkc
combin
chloroacetamid
electrophil
tetramethylrhodamin
fluorophor
success
label
pkc
jurkat
cell
demonstr
well
loss
signal
staurosporinepretr
cell
recent
design
probe
abelson
tyr
kinas
abl
base
anticanc
drug
imatinib
revers
mode
enzym
inhibit
necessit
incorpor
photoreact
benzophenon
moieti
dialdehyd
motif
coval
label
detect
enabl
incorpor
termin
alkyn
structur
allow
attach
rhodamin
azid
dye
cu
catalyz
triazol
format
click
chemistri
target
detect
abl
kinas
presenc
ad
cell
lysat
occur
label
effici
diminish
increas
amount
lysat
approach
extend
label
detect
endogen
level
revers
nonselect
kinas
inhibitor
staurosporin
also
util
recognit
motif
probe
design
sever
group
probe
design
coval
label
enabl
incorpor
photoreact
phenylazid
diazirin
group
irradi
uv
light
enrich
trap
protein
perform
incorpor
biotin
moieti
termin
alkyn
attach
either
biotin
group
fluorophor
detect
follow
coval
captur
click
chemistri
activ
base
probe
protein
tyrosin
phosphatas
ptp
develop
sever
scaffold
allow
mimicri
phosphotyrosin
motif
incorpor
reactiv
electrophil
coval
captur
activ
phosphatas
fig
sever
group
exploit
gener
quinon
methid
gener
reactiv
electrophil
trap
ptp
gener
substitut
phenyl
phosphat
benzyl
fluorid
substitu
ortho
para
posit
recent
public
concept
extend
design
unnatur
amino
acid
phosphotyrosin
incorpor
peptid
solid
phase
peptid
synthesi
spp
way
peptid
activ
base
probe
produc
base
known
ptp
target
sequenc
earlier
work
kumar
et
al
combin
minim
motif
incorpor
bromomethyl
phosphonatesubstitut
phenyl
deriv
attach
either
fluorophor
biotin
detect
success
label
ptp
demonstr
use
isol
enzym
vitro
cell
lysat
differ
cancer
cell
line
altern
approach
exploit
conjug
addit
substitut
aryl
vinyl
sulfon
sulfon
coval
label
activ
ptp
methodolog
appli
structur
studi
coval
complex
bacteri
ptp
yoph
mechan
base
inhibitor
recent
novel
probe
design
implement
enabl
microscopybas
read
use
quench
activ
base
probe
strategi
quencher
releas
upon
quinon
methid
format
reaction
target
enzym
methodolog
also
appli
oneand
twophoton
imag
experi
comparison
target
serthr
phosphatas
activitybas
probe
less
frequent
realiz
success
exampl
microcystin
deriv
probe
prepar
appli
label
isol
endogen
level
serthr
protein
phosphatas
jurkat
cell
lysat
acylphosph
kinas
probe
base
atp
cofactor
use
recent
extens
studi
evalu
specif
profil
rang
kinas
inhibitor
situ
nativ
kinas
profil
kinativ
approach
label
mammalian
cell
lysat
kinas
probe
conduct
presenc
absenc
respect
inhibitor
complex
sampl
digest
trypsin
biotinyl
peptid
enrich
streptavidin
resin
follow
elut
captur
peptid
analyz
quantit
proteom
experi
use
target
lcm
approach
detect
method
significantli
improv
signal
nois
ratio
allow
detect
lower
amount
analyt
quantit
inhibit
data
kinas
six
kinas
inhibitor
obtain
method
approach
provid
access
quantit
inhibit
profil
easili
obtain
experiment
approach
exploit
strength
activitybas
probe
profil
target
mass
spectrometrybas
proteom
introduct
activitybas
probe
develop
enzym
inhibitor
enabl
assess
compound
select
cellular
context
ideal
complement
convent
vitro
enzym
assay
allow
implement
assay
format
earli
stage
drug
develop
furthermor
competit
label
experi
greatli
aid
definit
specif
inhibitor
use
cellular
research
new
therapi
up
employ
manipul
dub
activ
highli
select
manner
achiev
desir
outcom
therefor
inhibit
select
intracellular
dub
activ
receiv
increas
attent
strategi
pharmacolog
intervent
diseas
dub
valid
role
oncolog
expect
first
line
futur
dub
inhibitor
provid
challeng
develop
specif
inhibitor
desir
compound
profil
overcom
expect
enabl
success
intervent
patholog
inflammatori
diseas
activitybas
probe
design
provid
insight
multipl
cellular
pathway
proven
extrem
valuabl
tool
studi
ptm
conjug
deconjug
enzym
investig
ubiquitin
proteasom
system
benefit
develop
probe
proteasom
proteolysi
well
deubiquityl
enzym
specif
overlap
reactiv
ubiquitinlik
proteas
investig
analog
ubl
probe
inhibitor
develop
facilit
competit
label
assay
enabl
elucid
inhibit
profil
cellular
environ
addit
natur
product
deriv
kinas
probe
demonstr
protein
target
coval
inhibitor
indic
previous
unknown
molecular
target
provid
inform
situat
specif
respect
compound
alway
fulli
elucid
import
access
select
inhibitor
basic
cell
biolog
drug
develop
make
area
highli
suit
success
industryacademia
collabor
